Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 4Phase 3 2Phase NA 1Phase 1 1

Status

Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Carcinoma, Ovarian Epithelial 3Ovarian Neoplasms 2

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × oregovomab × Clear all
NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

CanariaBio Inc.

Phase 1/2 Active not recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms

NCT03100006 2022-06-13

ORION-01

National Cancer Centre, Singapore

Phase 1/2 Terminated
13 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT04620954 2021-12-01

ORION-02

National Cancer Centre, Singapore

Phase 1/2 Unknown
31 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00034138 2007-12-18

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Unither Pharmaceuticals

Phase 1/2 Terminated
24 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡